NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q3 2025 Earnings Webinar.
An archived replay will be available after the call concludes on iMDX’s investor relations website at https://investors.imdxinc.com/.
Stephens NASH25 Conference
Separately, on November 19th, Chief Executive Officer Josh Riggs will attend the Stephens NASH25 Conference, taking place from November 18-20, 2025.
Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Stephens sales representative.
Event: Stephens NASH25 Conference
Dates: November 19, 2025
Location: Nashville, TN
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering precision diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. iMDx utilizes a well-established proprietary approach to quantify dd-cfDNA, which is a widely used molecular biomarker of transplant rejection.
iMDx™, GraftAssure™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.73 |
| Daily Volume: | 0 |
| Market Cap: | US$45.970M |
November 10, 2025 October 06, 2025 September 24, 2025 September 08, 2025 September 08, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
